Seventh stakeholders' forum on the implementation of the new pharmacovigilance legislation

EventCorporate

Bulgarian is available via eTranslation, the European Commission's machine translation service.

Translate to Bulgarian | Important information about machine translation

Date: петък, 27 September 2013, Цял ден
Местоположение: European Medicines Agency, Amsterdam, the Netherlands

This stakeholders' forum is intended to provide an update on key changes and aspects implemented since the sixth stakeholders' forum and to share positive and negative experiences on the implementation of the pharmacovigilance legislation across all stakeholders. Registration closed.

Documents

Agenda - Seventh stakeholders' forum on the implementation of the new pharmacovigilance legislation

Reference Number: EMA/422496/2013

English (EN) (67.56 KB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - Pharmacovigilance – risk-benefit monitoring cycle. A global undertaking (Fergus Sweeney)

English (EN) (162.17 KB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - PRAC’s perspective on implementation: strengthening public-health protection (June Raine)

English (EN) (2.11 MB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - Implementing the pharmacovigilance legislation: focus on European Union level activities (Peter Arlett)

English (EN) (2.27 MB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - Croatia’s perspective on implementation of the new pharmacovigilance legislation (Marina Dimov Di Giusti)

English (EN) (2.75 MB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - The new pharmacovigilance legislation. A national agency’s views (Sabine Straus)

English (EN) (2.16 MB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - July 2012 – September 2013: do patients see an impact of the new pharmacovigilance measures? (Franà§ois Houà¿ez)

English (EN) (3.97 MB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - European Patients Forum member survey on pharmacovigilance. First results and tentative conclusions (Kaisa Immonen-Charalambous)

English (EN) (681.36 KB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - Pharmacovigilance legislation present situation and perspectives for Polish patients (Rafal Swierzewski)

English (EN) (524.57 KB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - Making medicines affordable (Ana Maria Tomà©)

English (EN) (759.31 KB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - Industry perspective: Non-prescription medicines (Hubertus Cranz)

English (EN) (165.33 KB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - New European Union pharmacovigilance legislation. Innovative industry’s perspective on implementation. First year experience (Laurent Auclert)

English (EN) (133.82 KB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - Geriatrician’s perspective on implementation of the new pharmacovigilance legislation (Jean-Pierre Baeyens)

English (EN) (243.05 KB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - Implementation of the pharmacovigilance legislation. The views of physicians (Erzsà©bet Podmaniczky)

English (EN) (154.64 KB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Presentation - Implementation of the pharmacovigilance directive (John Chave)

English (EN) (769.12 KB - PDF)

Публикувано за първи път: 07/10/2013 Последна актуализация: 07/10/2013

Multimedia

Multimedia

Welcome and introduction

Implementing the pharmacovigilance legislation: what has been achieved?

PRAC's perspective on implementation

Member States' perspective on implementation

Member States' perspective on implementation

Patients' perspective on implementation

Patients' perspective on implementation

Patients' perspective on implementation

Industry's perspective on implementation

Industry's perspective on implementation

Industry's perspective on implementation

Healthcare professionals' perspective on implementation

Healthcare professionals' perspective on implementation

Healthcare professionals' perspective on implementation

Questions and Answers and conclusion